Nathan P, Hassel JC, Rutkowski P, et al. - Longer overall survival was achieved with tebentafusp, vs control therapy, in previously untreated patients suffering from metastatic uveal melanoma.

• Tebentafusp represents a bispecific protein comprising an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100–positive cells.

• This open-label, phase 3 trial involved 378 previously untreated HLA-A*02:01–positive patients with metastatic uveal melanoma.

• They were randomized to receive tebentafusp (tebentafusp group) or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified based on lactate dehydrogenase level.

• The intention-to-treat population showed 73% overall survival at 1 year in the tebentafusp group vs 59% in the control group (hazard ratio for death, 0.51).

• Tebentafusp resulted in significantly higher progression-free survival vs the control group (31% vs 19% at 6 months; hazard ratio for disease progression or death, 0.73).

• Cytokine-mediated events and skin-related events were the most common treatment-related adverse events with tebentafusp.

• These adverse events infrequently resulted in treatment discontinuation (2%).

• No treatment-related deaths occurred.